Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988414 | 0.98 | ALDH1A1 (0.40) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL11508728 | 0.79 | HTR1A (0.55) | ALDH1A1HTT | |
| SCHEMBL18051947 | 0.77 | ALDH1A1 (0.41) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12470961 | 0.77 | MAPT (0.55) | SMN1; SMN2MEN1KMT2AMMP1MMP3 | |
| SCHEMBL11506629 | 0.77 | HRH3 (0.49) | ALDH1A1 | |
| SCHEMBL14319076 | 0.76 | SMN1; SMN2 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL11689098 | 0.76 | ALDH1A1 (0.39) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4591291 | 0.76 | CHRNB2 (0.45) | ALDH1A1HPGDPOLB | |
| SCHEMBL3807935 | 0.76 | GNAI3 (0.42) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL378130 | 0.75 | MAPT (0.52) | ALDH1A1HPGDSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907805-B2 | Muscarinic M1 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157139-A1 | MUSCARINIC M1 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | ALDH1A1 1394/4885HPGD 2584/4885SMN1; SMN2 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.